Herborium Commences Amazon.com Sales for AcnEase
December 14 2010 - 8:30AM
Marketwired
Herborium Group, Inc., (PINKSHEETS: HBRM) www.herborium.com, a
Botanical Therapeutics™ company, today announced that it has
started selling AcnEase® www.acnease.com, its unique botanical acne
and Rosacea treatment, on Amazon.com. Sales on Amazon.co.uk will
commence later this week. This new distribution venue anticipates
revenue of $350,000-plus by the end of 2011 and is part of
Herborium's brand building efforts that will resonance in greater
revenue and will further the company's goal to become the worldwide
leader in Natural Acne Treatment and Preventative Therapy.
Conservative estimates suggest 50+ million people in the US
alone suffer from acne and over 17 million from Rosacea symptoms.
Currently the only class of FDA approved drugs to treat the cause
of acne is the isotretinoins, represented by Hoffman La-Roche's
product Accutane, which has recently been taken off the market due
to the number of severe side effects, and the resultant class
action suits. AcnEase represents a safe and
natural alternative for treatment of acne.
"The opportunity for sales of AcnEase -- a safe, all natural
botanical therapeutic on the Internet is extremely attractive,"
comments Dr. Agnes Olszewski, Herborium President and CEO.
"Worldwide business-to-consumer (B2C) sales over the Internet are
expected to reach $146 billion in 2010 while the potential value of
e-commerce is estimated to be over $800 billion. In addition The
Health Care Distribution Management Association (HDMA) in its 'HDMA
Industry Profile and Health Care Fact Book' clearly indicated that
one of the major forces shaping the industry today is the
increasingly important role of the Internet in the distribution of
healthcare products," adds Dr. Olszewski.
The new distribution arrangements are another example of
Herborium's "Road-to-Market" Strategy calling for revenue
projections of $7.5 Million, as detailed ("Road-to-Market"
Strategy), with the ultimate goal to eventually capture 1% of the
Global Natural and Alternative Treatments Market.
About Herborium Group, Inc. Herborium
Group, Inc., a Botanical Therapeutics® company, focuses on
developing, licensing, and marketing proprietary, botanically based
medicinal products to consumers and healthcare professionals. The
Company's business model focuses on emerging market opportunities
spearheaded by the growth of a new market sector located between
high-cost, high-risk, ethical pharmaceuticals and commoditized
classic nutraceuticals (supplements). The Company uses clinical
validation and a proactive regulatory strategy based on the FDA
Guidance for Industry: Botanical Drug Products (FDA Guidance 2004)
to establish and maintain a differential advantage. For more
information, please visit www.herborium.com and
www.acnease.com.
One of our most important responsibilities is to communicate
with shareholders in an open and direct manner. Comments are based
on current management expectations, and are considered
"forward-looking statements," generally preceded by words such as
"plans," "expects," "believes," "anticipates," or "intends." We
cannot promise future returns. Our statements reflect our best
judgment at the time they are issued, and we disclaim any
obligation to update or alter forward-looking statements as the
result of new information or future events. The Company urges
investors to review the risks and uncertainties contained within
its filings with the OTC Markets and/or Securities and Exchange
Commission.
Company Contact: Steve Haag Investor Relations (832)
413-6206
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jun 2024 to Jul 2024
Herborium (PK) (USOTC:HBRM)
Historical Stock Chart
From Jul 2023 to Jul 2024